Personalizing therapy in advanced non-small cell lung cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 6, 2013, Pages 822-836

  Villaruz, Liza C ^a   Burns, Timothy F ^a   Ramfidis, Vasilis S ^a   Socinski, Mark A ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

non small cell lung cancer; oncogenic driver mutations; personalized therapy

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; ANTINEOPLASTIC AGENT; BRIVANIB; BRIVANIB ALANINATE; CABOZANTINIB; CARBOPLATIN; CETUXIMAB; CH 5424802; CISPLATIN; CRIZOTINIB; DASATINIB; DOCETAXEL; ERLOTINIB; GANETESPIB; GEFITINIB; GEMCITABINE; LDK 378; LUMINESPIB; ONARTUZUMAB; PACLITAXEL; PEMETREXED; PONATINIB; RETASPIMYCIN; RIDAFOROLIMUS; SELUMETINIB; TIVANTINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; FINE NEEDLE ASPIRATION BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METASTATIC MELANOMA; MOLECULAR DIAGNOSIS; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEAT PROCEDURE; SOLID TUMOR; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING;

EID: 84884571733     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1358552     Document Type: Article

References (156)

1. Howlader N., Noone A. M., Krapcho M., et al. SEER Stat Fact Sheets: Lung and Bronchus. 2010. Access date: October 31, 2013. http://seercancergov/csr/ 1975-2008/
2. Hopwood P., Stephens R. J.; The Medical Research Council (MRC) Lung Cancer Working Party. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br J Cancer: 1995; 71 3 633 636
3. Burdett S., Stephens R., Stewart L., et al. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol: 2008; 26 28 4617 4625
4. Burdett S., Stewart L., Pignon J-P. Chemotherapy in non-small cell lung cancer: an update of an individual patient data-based meta-analysis. J Thorac Cardiovasc Surg: 2005; 129 5 1205, author reply 1205-1206
5. Rapp E., Pater J. L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer report of a Canadian multicenter randomized trial. J Clin Oncol: 1988; 6 4 633 641
6. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ: 1995; 311 7010 899 909
7. Fossella F., Pereira J. R., von Pawel J., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol: 2003; 21 16 3016 3024 (Pubitemid 46606280)
8. Kelly K., Crowley J., Bunn P. A. Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol: 2001; 19 13 3210 3218 (Pubitemid 32591438)
9. Scagliotti G. V., De Marinis F., Rinaldi M., et al. Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol: 2002; 20 21 4285 4291 (Pubitemid 35266288)
10. Schiller J. H., Harrington D., Belani C. P., et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med: 2002; 346 2 92 98 (Pubitemid 34438899)
11. Zatloukal P., Petruzelka L., Zemanová M., et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer: 2003; 41 3 321 331 (Pubitemid 36970188)
12. Lynch T. J., Bell D. W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med: 2004; 350 21 2129 2139 (Pubitemid 38637993)
13. Paez J. G., Jänne P. A., Lee J. C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science: 2004; 304 5676 1497 1500 (Pubitemid 38720929)
14. Kwak E. L., Bang Y. J., Camidge D. R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med: 2010; 363 18 1693 1703
15. Bergethon K., Shaw A. T., Ou S. H., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol: 2012; 30 8 863 870
16. Ou S. I., Bang Y., Camidge D. R., et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8032
17. Dogan S., Shen R., Ang D. C., et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res: 2012; 18 22 6169 6177
18. Centers for Disease Control and Prevention (CDC) Annual smoking-attributable mortality, years of potential life lost, and productivity losses United States, 1997-2001. MMWR Morb Mortal Wkly Rep: 2005; 54 25 625 628
19. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin: 2008; 58 2 71 96 (Pubitemid 351521864)
20. Thun M. J., Henley S. J., Burns D., Jemal A., Shanks T. G., Calle E. E. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst: 2006; 98 10 691 699 (Pubitemid 43832505)
21. Johnson B. E., Kris M. G., Berry L. D., et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC) [abstract]. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8019
22. Herbst R. S., Heymach J. V., Lippman S. M. Lung cancer. N Engl J Med: 2008; 359 13 1367 1380
23. Sharma S. V., Bell D. W., Settleman J., Haber D. A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer: 2007; 7 3 169 181
24. Mok T. S., Wu Y. L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med: 2009; 361 10 947 957
25. Rosell R., Carcereny E., Gervais R., et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol: 2012; 13 3 239 246
26. Zhou C., Wu Y. L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol: 2011; 12 8 735 742
27. Maemondo M., Inoue A., Kobayashi K., et al. North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med: 2010; 362 25 2380 2388
28. Mitsudomi T., Morita S., Yatabe Y., et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol: 2010; 11 2 121 128
29. Sequist L. V., Yang J. C., Yamamoto N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol: 2013; 31 27 3327 3334
30. Wu Y. L., Zhou C., Hu C., et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinab (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung [abstract]. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8016
31. Fukuoka M., Wu Y. L., Thongprasert S., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol: 2011; 29 21 2866 2874
32. Mok T., Yang J. J., Lam K. C. Treating patients with EGFR-sensitizing mutations: first line or second line is there a difference? J Clin Oncol: 2013; 31 8 1081 1088
33. Arcila M. E., Oxnard G. R., Nafa K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res: 2011; 17 5 1169 1180
34. Yu H. A., Arcila M. E., Rekhtman N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res: 2013; 19 8 2240 2247
35. Miller V. A., Hirsh V., Cadranel J., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol: 2012; 13 5 528 538
36. Regales L., Gong Y., Shen R., et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest: 2009; 119 10 3000 3010
37. Takezawa K., Pirazzoli V., Arcila M. E., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov: 2012; 2 10 922 933
38. Ohashi K., Sequist L. V., Arcila M. E., et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A: 2012; 109 31 E2127 E2133
39. Sequist L. V., Waltman B. A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med: 2011; 3 75 75ra26
40. Bean J., Brennan C., Shih J. Y., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A: 2007; 104 52 20932 20937
41. Engelman J. A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science: 2007; 316 5827 1039 1043 (Pubitemid 46799492)
42. Chiarle R., Voena C., Ambrogio C., Piva R., Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer: 2008; 8 1 11 23
43. Soda M., Choi Y. L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature: 2007; 448 7153 561 566 (Pubitemid 47206930)
44. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol: 2009; 27 26 4232 4235
45. Chen Z., Sasaki T., Tan X., et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res: 2010; 70 23 9827 9836
46. McDermott U., Iafrate A. J., Gray N. S., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res: 2008; 68 9 3389 3395
47. Soda M., Takada S., Takeuchi K., et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A: 2008; 105 50 19893 19897
48. Shaw A. T., Yeap B. Y., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol: 2009; 27 26 4247 4253
49. Wong D. W., Leung E. L., So K. K., et al. University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer: 2009; 115 8 1723 1733
50. Camidge D. R., Bang Y. J., Kwak E. L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol: 2012; 13 10 1011 1019
51. Kim D. W., Ahn M. J., Shi Y. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer [abstract]. J Clin Oncol 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 30(15): 7533
52. Shaw A. T., Yeap B. Y., Solomon B. J., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol: 2011; 12 11 1004 1012
53. Shaw A. T., Kim D. W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med: 2013; 368 25 2385 2394
54. Choi Y. L., Soda M., Yamashita Y., et al. ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med: 2010; 363 18 1734 1739
55. Katayama R., Khan T. M., Benes C., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A: 2011; 108 18 7535 7540
56. Lovly C. M., Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med: 2012; 4 120 ps2
57. Doebele R. C., Pilling A. B., Aisner D. L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res: 2012; 18 5 1472 1482
58. Katayama R., Shaw A. T., Khan T. M., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med: 2012; 4 120 20ra17
59. Sasaki T., Koivunen J., Ogino A., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res: 2011; 71 18 6051 6060
60. Shaw A. T., Mehra R., Kim D. W., et al. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC [abstract]. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8010
61. Nakagawa K., Kiura K., Nishio M., et al. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP [abstract]. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8033
62. Socinski M. A., Goldman J., El-Hariry I., et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res: 2013; 19 11 3068 3077
63. Garon E. B., Moran T., Barlesi F., et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 30(15): 7543
64. Sequist L. V., Gettinger S., Senzer N. N., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol: 2010; 28 33 4953 4960
65. Ou S. H., Tan J., Yen Y., Soo R. A. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev Anticancer Ther: 2012; 12 4 447 456
66. Shaw A. T., Camidge D. R., Engelman J. A., et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement [abstract]. J Clin Oncol 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 30(15): 7508
67. Birchmeier C., O'Neill K., Riggs M., Wigler M. Characterization of ROS1 cDNA from a human glioblastoma cell line. Proc Natl Acad Sci U S A: 1990; 87 12 4799 4803
68. Birchmeier C., Sharma S., Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A: 1987; 84 24 9270 9274
69. Charest A., Lane K., McMahon K., et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer: 2003; 37 1 58 71 (Pubitemid 36417922)
70. Charest A., Wilker E. W., McLaughlin M. E., et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res: 2006; 66 15 7473 7481 (Pubitemid 44289201)
71. Chin L. P., Soo R. A., Soong R., Ou S. H. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol: 2012; 7 11 1625 1630
72. Takeuchi K., Soda M., Togashi Y., et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med: 2012; 18 3 378 381
73. Rimkunas V. M., Crosby K. E., Li D., et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res: 2012; 18 16 4449 4457
74. Davies H., Bignell G. R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature: 2002; 417 6892 949 954 (Pubitemid 34716871)
75. Tol J., Nagtegaal I. D., Punt C. JA. BRAF mutation in metastatic colorectal cancer. N Engl J Med: 2009; 361 1 98 99
76. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol: 2010; 11 8 753 762
77. Paik P. K., Arcila M. E., Fara M., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol: 2011; 29 15 2046 2051
78. Bollag G., Tsai J., Zhang J., et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov: 2012; 11 11 873 886
79. Gautschi O., Pauli C., Strobel K., et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol: 2012; 7 10 e23 e24
80. Peters S., Michielin O., Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol: 2013; 31 20 e341 e344 [Epub ahead of print]
81. Planchard D., Mazieres J., Riely G. J., et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8009
82. Rudin C. M., Hong K., Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol: 2013; 8 5 e41 e42
83. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol: 2011; 12 2 175 180
84. Gherardi E., Birchmeier W., Birchmeier C., Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer: 2012; 12 2 89 103
85. Sadiq A. A., Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol: 2013; 31 8 1089 1096
86. Ma P. C., Jagadeeswaran R., Jagadeesh S., et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res: 2005; 65 4 1479 1488 (Pubitemid 40270177)
87. Beau-Faller M., Ruppert A. M., Voegeli A. C., et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol: 2008; 3 4 331 339 (Pubitemid 351489471)
88. Onitsuka T., Uramoto H., Ono K., et al. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol: 2010; 5 5 591 596
89. Onozato R., Kosaka T., Kuwano H., Sekido Y., Yatabe Y., Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol: 2009; 4 1 5 11
90. Spigel D. R., Ervin T. J., Ramlau R., et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J Clin Oncol 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 29(15): 7505
91. Peters S., Adjei A. A. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol: 2012; 9 6 314 326
92. Ou S. H., Kwak E. L., Siwak-Tapp C., et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol: 2011; 6 5 942 946
93. Chi A. S., Batchelor T. T., Kwak E. L., et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol: 2012; 30 3 e30 e33
94. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol: 1999; 17 1 380 393 (Pubitemid 29022417)
95. Phay J. E., Shah M. H. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res: 2010; 16 24 5936 5941
96. Blaugrund J. E., Johns M. M. Jr, Eby Y. J., et al. RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet: 1994; 3 10 1895 1897 (Pubitemid 24310493)
97. Grieco M., Santoro M., Berlingieri M. T., et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell: 1990; 60 4 557 563
98. Santoro M., Dathan N. A., Berlingieri M. T., et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene: 1994; 9 2 509 516 (Pubitemid 24041530)
99. Nikiforov Y. E., Nikiforova M. N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol: 2011; 7 10 569 580
100. Wells S. A. Jr, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res: 2009; 15 23 7119 7123
101. Jhiang S. M. The RET proto-oncogene in human cancers. Oncogene: 2000; 19 49 5590 5597
102. Takeuchi K., Choi Y. L., Togashi Y., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res: 2009; 15 9 3143 3149
103. Kohno T., Ichikawa H., Totoki Y., et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med: 2012; 18 3 375 377
104. Wang R., Hu H., Pan Y., et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol: 2012; 30 35 4352 4359
105. Gautschi O., Zander T., Keller F. A., et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol: 2013; 8 5 e43 e44
106. Spector N. L., Blackwell K. L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol: 2009; 27 34 5838 5847
107. Stephens P., Hunter C., Bignell G., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature: 2004; 431 7008 525 526
108. Gatzemeier U., Groth G., Butts C., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol: 2004; 15 1 19 27 (Pubitemid 38139598)
109. Arcila M. E., Chaft J. E., Nafa K., et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res: 2012; 18 18 4910 4918
110. Shigematsu H., Takahashi T., Nomura M., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res: 2005; 65 5 1642 1646 (Pubitemid 40478587)
111. Tomizawa K., Suda K., Onozato R., et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer: 2011; 74 1 139 144
112. Mazières J., Peters S., Lepage B., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol: 2013; 31 16 1997 2003
113. Chaft J. E., Arcila M. E., Paik P. K., et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther: 2012; 11 2 485 491
114. Bendell J. C., Rodon J., Burris H. A., et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol: 2012; 30 3 282 290
115. Shapiro G., Kwak E. L., Baselga J., et al. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors [abstract]. J Clin Oncol 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 27(15S): 3500
116. Ding L., Getz G., Wheeler D. A., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature: 2008; 455 7216 1069 1075
117. Malanga D., Scrima M., De Marco C., et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle: 2008; 7 5 665 669 (Pubitemid 351499006)
118. Yap T. A., Yan L., Patnaik A., et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol: 2011; 29 35 4688 4695
119. Marks J. L., Gong Y., Chitale D., et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res: 2008; 68 14 5524 5528
120. Jänne P. A., Shaw A. T., Pereira J. R., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol: 2013; 14 1 38 47
121. Gandara D., Hiret S., Blumenschein G. R., et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial [abstract]. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8028
122. Becerra C., Infante J. R., Garbo L. E., et al. A five-arm, open-label, phase I/Ib study to access safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib(GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors [abstract]. J Clin Oncol 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 30(15): 3023
123. Doebele R. C., Vaishnavi A., Capelletti M., et al. NTRK1 gene fusions as a novel oncogene target in lung cancer [abstract]. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8023
124. Mo M. L., Chen Z., Zhou H. M., et al. Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer. J Exp Clin Cancer Res: 2013; 32 29
125. Bicocca V. T., Chang B. H., Masouleh B. K., et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell: 2012; 22 5 656 667
126. Karnoub A. E., Weinberg R. A. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol: 2008; 9 7 517 531 (Pubitemid 351881844)
127. Nakano H., Yamamoto F., Neville C., Evans D., Mizuno T., Perucho M. Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-ras oncogenes. Proc Natl Acad Sci U S A: 1984; 81 1 71 75 (Pubitemid 14180829)
128. Santos E., Martin-Zanca D., Reddy E. P., Pierotti M. A., Della Porta G., Barbacid M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science: 1984; 223 4637 661 664 (Pubitemid 14186799)
129. Riely G. J., Marks J., Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc: 2009; 6 2 201 205
130. Mascaux C., Iannino N., Martin B., et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer: 2005; 92 1 131 139 (Pubitemid 40188446)
131. Riely G. J., Kris M. G., Rosenbaum D., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res: 2008; 14 18 5731 5734
132. Ihle N. T., Byers L. A., Kim E. S., et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst: 2012; 104 3 228 239
133. Villaruz L. C., Socinski M. A., Cunningham D. E., et al. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma. Cancer: 2013; 119 12 2268 2274
134. Yu H. A., Sima C. S., Shen R., et al. Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13 [abstract]. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8025
135. Jänne P. A., Shaw A. T., Pereira J. R., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol: 2013; 14 1 38 47
136. Sequist L. V., von Pawel J., Garmey E. G., et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol: 2011; 29 24 3307 3315
137. Acquaviva J., Smith D. L., Sang J., et al. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther: 2012; 11 12 2633 2643
138. De Raedt T., Walton Z., Yecies J. L., et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell: 2011; 20 3 400 413
139. O'Byrne K. J., Bondarenko I., Barrios C., et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study [abstract]. ASCO Meeting Abstracts 2009; J Clin Oncol 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 27(15S): 8007
140. Fennell D. A., Goss G. D., Socinski M. A., et al. GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma [abstract]. J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): TPS8126
141. Riely G. J., Brahmer J. R., Planchard D., et al. A randomzied discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations [abstract]. J Clin Oncol 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 30(15): 7531
142. Rekhtman N., Paik P. K., Arcila M. E., et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res: 2012; 18 4 1167 1176
143. Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature: 2012; 489 7417 519 525
144. Weiss J., Sos M. L., Seidel D., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med: 2010; 2 62 62ra93
145. Dutt A., Ramos A. H., Hammerman P. S., et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE: 2011; 6 6 e20351
146. Ratain M. J., Schwartz G. K., Oza A. M., et al. Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT) [abstract]. J Clin Oncol 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 29(15): 3079
147. Hammerman P. S., Sos M. L., Ramos A. H., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov: 2011; 1 1 78 89
148. Shayesteh L., Lu Y., Kuo W. L., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet: 1999; 21 1 99 102 (Pubitemid 29036292)
149. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science: 2004; 304 5670 554 (Pubitemid 38541907)
150. Sansal I., Sellers W. R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol: 2004; 22 14 2954 2963 (Pubitemid 41079915)
151. Lee J. W., Soung Y. H., Kim S. Y., et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene: 2005; 24 8 1477 1480 (Pubitemid 40343128)
152. Yamamoto H., Shigematsu H., Nomura M., et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res: 2008; 68 17 6913 6921
153. Kawano O., Sasaki H., Okuda K., et al. PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer: 2007; 58 1 159 160 (Pubitemid 47379973)
154. Paik P. K., Moreira A. L., Wang L., et al. Patterns of metastasis and survival in patients with PI3K pathway-driven stage IV squamous cell lung cancers (SQCLC). J Clin Oncol 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8022
155. Spoerke J. M., O'Brien C., Huw L., et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res: 2012; 18 24 6771 6783
156. Han J. Y., Park K., Kim S. W., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol: 2012; 30 10 1122 1128